EPRX Stock Analysis: Buy, Sell, or Hold?
EPRX - Eupraxia Pharmaceuticals Inc. Common Stock
$6.33
-0.32 (-4.81%)
▼
5d:
-11.84%
30d:
-14.69%
90d:
-22.62%
HOLD
MODERATE Confidence
Analysis Updated: Jun 3, 2026 12:00 AM ET
Earnings: May 12, 2026
0d
Get Alerted When EPRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: EPRX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: EPRX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: EPRX is currently trading at $6.33, which is considered oversold relative to its 30-day fair value range of $6.75 to $7.59.
Technical Outlook: Technically, EPRX is in a strong downtrend. The price is currently testing key support at $6.26. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.8% recently.
Market Sentiment: EPRX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $16.28 (+157.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, EPRX is in a strong downtrend. The price is currently testing key support at $6.26. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.8% recently.
Market Sentiment: EPRX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $16.28 (+157.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$6.75 -
$7.59
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.8%)
- BULLISH: Trading 157.2% below Wall St target ($16.28)
- CAUTION: 5-day price weakness (-11.8%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$6.75 -
$7.59
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$6.26
Resistance Level
$7.55
Current Trend
Strong Downtrend
Technical data as of
Jun 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.85
Wall Street Target
$16.28
(+157.2%)
Share & Embed Analysis
Last updated: June 03, 2026 5:09 PM ET
Data refreshes hourly during market hours. Next update: 6:09 PM
Data refreshes hourly during market hours. Next update: 6:09 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EPRX showing a specific setup today?
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 54 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1023 | 53 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$82 | 58 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$297 | 57 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 48 HOLD |
